Wall Street Zen Upgrades Tvardi Therapeutics (NASDAQ:TVRD) to Hold

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

TVRD has been the topic of a number of other research reports. Barclays set a $5.00 target price on Tvardi Therapeutics and gave the company an “equal weight” rating in a research note on Monday, October 13th. Cantor Fitzgerald cut Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 13th. Raymond James Financial lowered Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 14th. Weiss Ratings reiterated a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 29th. Finally, BTIG Research lowered their target price on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, October 13th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $55.50.

Tvardi Therapeutics Trading Down 1.0%

Shares of TVRD opened at $3.89 on Tuesday. The company’s fifty day simple moving average is $4.13 and its 200-day simple moving average is $18.40. The company has a market cap of $36.49 million, a P/E ratio of -0.40 and a beta of 0.09. Tvardi Therapeutics has a twelve month low of $3.74 and a twelve month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24.

Institutional Investors Weigh In On Tvardi Therapeutics

Several hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC purchased a new position in shares of Tvardi Therapeutics during the second quarter valued at $2,617,000. JPMorgan Chase & Co. bought a new position in Tvardi Therapeutics during the 2nd quarter worth about $39,000. New York State Common Retirement Fund purchased a new position in Tvardi Therapeutics during the 2nd quarter valued at about $92,000. Marshall Wace LLP purchased a new position in Tvardi Therapeutics during the 2nd quarter valued at about $583,000. Finally, Slate Path Capital LP bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at about $16,427,000. 44.66% of the stock is currently owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.